Barclays Maintains an 'Overweight' on Sequenom (SQNM); Analyst Day Sets Initial T21 Expectations
Tweet
Share
E-mailGet Alerts SQNM Hot Sheet
Price: $2.39 --0%
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Join SI Premium – FREE
Barclays maintains an 'Overweight' on Sequenom (NASDAQ: SQNM) price target of $9.00.
Barclays analyst says, "Management laid out three possible scenarios for 2012 test uptake - a 'low' case of 25K units on an annualized basis, 'medium' of 40K units and a 'high' of 60K units. Key gating factors for test adoption, in our view, are physician education (clarity around clinical-use protocols, industry guidelines) and patient convenience (physician office based blood collection by 2H12). TAT is 8-10 days and SQNM's suggested protocol encourages physicians to consider MaterniT21 in the first trimester for the majority of high-risk women (details on page 3). SQNM is currently reporting T13/18 results, and over time, expects to add other chromosomal abnormalities. PMA submission is expected sometime in 2013, and approval will accelerate adoption."
"Reimbursement, while a crucial factor for profitability, should not be a significant
hurdle for demand: We believe the MaterniT21 test is attractive for patients at a
maximum out of pocket cost of $235..."
For an analyst ratings summary and ratings history on Sequenom click here. For more ratings news on Sequenom click here.
Shares of Sequenom closed at $4.24 yesterday.
Barclays analyst says, "Management laid out three possible scenarios for 2012 test uptake - a 'low' case of 25K units on an annualized basis, 'medium' of 40K units and a 'high' of 60K units. Key gating factors for test adoption, in our view, are physician education (clarity around clinical-use protocols, industry guidelines) and patient convenience (physician office based blood collection by 2H12). TAT is 8-10 days and SQNM's suggested protocol encourages physicians to consider MaterniT21 in the first trimester for the majority of high-risk women (details on page 3). SQNM is currently reporting T13/18 results, and over time, expects to add other chromosomal abnormalities. PMA submission is expected sometime in 2013, and approval will accelerate adoption."
"Reimbursement, while a crucial factor for profitability, should not be a significant
hurdle for demand: We believe the MaterniT21 test is attractive for patients at a
maximum out of pocket cost of $235..."
For an analyst ratings summary and ratings history on Sequenom click here. For more ratings news on Sequenom click here.
Shares of Sequenom closed at $4.24 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Upgrades Taylor Devices, Inc. (TAYD) to Buy
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
- BMO Capital Starts Marvell (MRVL) at Outperform
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
